Part I. The Background, the Debate, and the Ethics Involved1. Drug Testing and Pregnant Women: Background and Significance2. The Rationales For and Against Inclusion3. The Ethics Involved
Part II. Quantitative and Qualitative Discoveries4. A Measure of Exclusion5. Perspectives from the Industry: On Exclusion6. Perspectives from the Industry: On Inclusion7. Perspectives from the Industry: On Litigation, Regulation, Incentives, and Indemnity8. Perspectives from the Industry: On Ethics
Part III. Uniting the Regulators, the Industry, and the Advocates9. The FDA Guidance, Public Comment, and Affinity with Stakeholders10. Proposed Actions for FDA and the Pharmaceutical Industry11. A Chance at Change12. After the Guidance
AppendicesFDA Guidance Document - Pregnant Women: Scientific and Ethical Consideration for Inclusion in Clinical TrialsTaskforce on Research Specific to Pregnant Women and Lactating Women: Report to the Secretary, Health and Human Services. Executive Summary
Dr. Shields is an OB/GYN nurse practitioner with a doctoral degree in Public Health. As a clinician she provided inpatient and ambulatory care in obstetrics and gynecology. As an epidemiologist she was responsible for the development and operation of the Pregnancy Registry Program at Merck, one of the earliest and most comprehensive pregnancy registry programs within the pharmaceutical industry. As a researcher/writer, she has published scientific papers in Obstetrics & Gynecology, Pediatrics, Birth Defects Research and other medical journals. Dr. Shields is most widely known for her research into medication safety during pregnancy.